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Article Summary: Arterial stiffness is increased in Malawian adults with low CD4 during 
the first 3 months of antiretroviral therapy, compared to adults without HIV. Hypertension is 
an important traditional risk factor and immune activation, including CD8 exhaustion, also 
contributes to arterial stiffness.
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Abstract (199 words) 
Background 
The contribution of immune activation to arterial stiffness and its reversibility in HIV-infected adults 
in sub-Saharan Africa is unknown.  
Methods 
HIV-uninfected and HIV-infected Malawian adults initiating antiretroviral therapy (ART) with CD4 
<100 cells/l were enrolled (2-weeks post-ART for HIV-infected) and followed for 44-weeks. We 
evaluated the relationship between carotid femoral pulse wave velocity (cfPWV) and T-cell activation 
(HLADR+CD38+), exhaustion (PD1+) and senescence (CD57+), and monocyte subsets using normal 
regression. 
Results 
In 279 HIV-infected and 110 HIV-uninfected adults, 142(37%) had hypertension. HIV was 
independently associated with 12% higher cfPWV (p=0.02) at baseline, and week-10 (14% higher, 
p=0.02) but resolved by week-22. CD4 and CD8 T-cell exhaustion(PD1+) were independently 
associated with higher cfPWV at baseline (p=0.02). At 44-weeks, arterial stiffness improved more in 
those with greater decreases in %CD8 and %CD8PD1+ T-cells (p=0.01, p=0.03 respectively). When 
considering HIV-infected participants alone, adjusted arterial stiffness at week-44 tended to be lower 
in those with higher baseline %CD8PD1+ T-cells (p=0.054).  
Conclusions 
PD-1+ expressing CD8 T-cells are associated with HIV-related arterial stiffness, which remains 
elevated during the first three months on ART. Resources to prevent cardiovascular disease in sub-
Saharan Africa should focus on blood pressure reduction, and those with low CD4 during early ART.    
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Word count: 3500 
Introduction 
 
Sub-Saharan Africa (SSA) has the highest burden of HIV worldwide, with 25.6 million people living 
with the disease.[1] The region  also faces an accelerated epidemic of non-communicable diseases 
including cardiovascular disease (CVD).[2] Mortality from CVD is high in SSA, causing an estimated 
one million deaths per year.[3] This rate is predicted to increase, with non-communicable disease-
related mortality estimated to surpass infection-related deaths by 2030.[3] Studies from high-income 
settings suggest the risk of CVD is approximately doubled in people living with HIV, even after 
adjusting for confounders such as socio-economic status, traditional cardiovascular risk factors and 
viral hepatitis co-infection.[4, 5] Several processes may contribute, including high HIV viral load, 
side-effects of antiretroviral therapy (ART) - particularly protease-inhibitors, and the effects of 
chronic immune activation despite effective ART.[6] Immune activation may be driven by persistent 
low level HIV viraemia, microbial translocation, and subclinical infections.[7, 8] However, the risk of 
CVD in people living with HIV in SSA has not been well characterised. It is likely that immune 
activation differs in low-income settings due to the effects of more advanced HIV disease at 
presentation, more frequent acute coinfections, and malnutrition with disruption to the gut barrier.[9, 
10] Traditional cardiovascular risk factors also vary, with hypertension being more prevalent than 
diabetes, dyslipidaemia or obesity - although with epidemiological transition and increasing 
urbanisation in the region, this may change in the near future.[11, 12]  
 
Large cohorts documenting cardiovascular events have not been established in SSA, limiting the 
assessment of cardiovascular risk. One physiological marker of cardiovascular risk is  carotid femoral 
pulse wave velocity (cfPWV), a gold standard measurement of arterial stiffness.[13-15] Although 
adjusted for concurrent blood pressure, the reading can be affected by blood viscosity and ambient 
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temperature.[13] Nevertheless it has been shown to be reliable and reproducible, and has been 
validated against clinical outcomes in high-income settings;[16-18] a cfPWV in the top versus bottom 
tertile is associated with a greater than 2-fold increased risk of myocardial infarction/stroke.[18]  The 
2007 European Society of Cardiology consensus guidelines proposed a 12m/s threshold as high risk 
for CVD events.[14]  A few small studies have assessed arterial stiffness in people living with HIV in 
low-income SSA,[19-23] but none have evaluated the impact of chronic immune activation over time.  
 
This study therefore aimed to characterise the contribution of immune activation to arterial stiffness in 
HIV-infected Malawian adults initiating ART with advanced immune suppression, in comparison to 
HIV-uninfected adults, and to determine how this changed over time on ART.  
 
Methods 
 
Study design 
Adults over 18 years old presenting for HIV testing at the voluntary testing clinic, the HIV outpatient 
clinic and the medical inpatient wards at the Queen Elizabeth Central Hospital, Blantyre, Malawi 
were recruited into a prospective cohort from January 2014 until June 2015. Adults with a new HIV 
diagnosis were approached consecutively and were eligible if they were ART-naïve, had CD4 <100 
cells/uL and provided informed written consent. Adults who were confirmed HIV-uninfected, after 
self-presenting for an asymptomatic HIV test at the same voluntary testing clinic, were eligible if they 
had  no current illness and no history of infection in the previous month  by clinician assessment and 
medical notes review, and provided informed written consent. Exclusion criteria were living outside 
the Blantyre area, inability to attend follow-up visits, pregnancy, or being too unwell to participate as 
judged by the study clinicians. Because HIV-uninfected participants were younger, an exclusion 
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criterion of <35 years was applied for this group from March 2014. From January 2014 until January 
2015, HIV-infected participants were co-recruited with the REALITY trial (NCT01825031). 
REALITY assessed interventions to reduce early mortality following ART initiation in those with 
CD4<100 cells/µL. Participants were simultaneously randomised to three study interventions in 
addition to standard triple-drug ART and cotrimoxazole; 12 weeks’ adjunctive raltegravir, a package 
of opportunistic infection prophylaxis, and/or Ready to Use Supplementary Food.[24-26] 
 
At enrolment and 44 weeks later, participants underwent a detailed clinical assessment including 
traditional cardiovascular risk factors and infection history, and fasting blood draw including sodium 
citrate-containing samples for immunophenotyping. To reduce the burden of study participation, and 
to ensure starting ART was prioritised in the severely immunosuppressed HIV-infected population,  
the baseline study visit was conducted at week 2 following ART initiation. cfPWV was assessed on 
all participants at enrolment, and 10, 22 and 44 weeks later. All participants provided informed 
written consent and ethical approval was granted by the College of Medicine Research and Ethics 
Committee (COMREC), University of Malawi (P.09/13/1464) and the University of Liverpool 
Research and Ethics Committee (UoL000996).  
 
Outcome measurement  
cfPWV was measured using a Vicorder device (Skidmore Medical, London, UK). The distance was 
the length from the sternal notch to the umbilicus and then the top mid-point of the femoral cuff, 
multiplied by 0.8 as per consensus guidelines. Wave forms were saved and a random sample was 
reviewed by an experienced independent assessor, blinded to HIV status, at three time points during 
the study to ensure consistent quality. The intra-operator concordance correlation coefficient for 10 
participants was 0.99 (95%CI 0.96–1.00). 
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Immunophenotyping of peripheral blood mononuclear cells 
For flow cytometry, whole blood was processed within 4 hours of collection to isolate peripheral 
blood mononuclear cells (PBMCs) using Lymphoprep (Axis-Shields-Diagnostics) as previously 
described.[27] Cells were analysed using a CyAn ADP 9 colour flow cytometer (Beckman Coulter). 
The T-cell panel included CD3 BV510, CD4 V450, CD38 PE Cy7, HLA-DR AF700, PD1 APC, and 
CD57 FITC (all from BD Biosciences) and CD8 PE (Biolegend). The monocyte panel included HLA-
DR AF700, CD14 PE Cy7 and CD16 PE (all from BD Biosciences). Anti-mouse Igk isotype control 
and negative control particles (BD biosciences) were used for compensation. A standardised gating 
strategy was followed for both panels (T-cells Supplementary Figure 1A, monocytes Supplementary 
Figure 1B). Monocyte subsets were identified as previously.[28]  
 
Statistical analysis 
As data validating a clinically relevant cfPWV threshold in SSA were not available, the 12m/s 
threshold in European consensus guidance was used to guide sample size calculations.[14] Recruiting 
300 HIV-infected and 100 HIV-uninfected participants provided 80% power to detect an odds ratio 
(OR) of 1.5 associated with HIV, assuming 25% of HIV-uninfected participants had cfPWV >12 
m/s.[14] After enrolment, it was clear that this threshold was rarely reached, and therefore the planned 
analysis considered the primary outcome, cfPWV, as a continuous variable.  
Factors affecting HIV and arterial stiffness were identified a priori using a causal diagram 
(Supplementary Figure 2) as either potential mediators (on the mechanistic pathway between them) or 
confounders (associated with HIV and arterial stiffness but not on the mechanistic pathway). 
Categorical and continuous variables were compared between HIV-infected and uninfected adults 
using chi-squared and rank-sum tests, respectively. Correlations between continuous variables were 
compared using Spearman’s rho. To avoid undue influence from outliers, continuous variables were 
truncated at their 97.5% and 2.5% percentiles for regression models. Normal linear regression models 
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were constructed, with log10 cfPWV (approximately normal) as the outcome, and HIV infection as 
the primary exposure. Confounders and mediators with univariate p value <0.2 for association with 
cfPWV were considered and backwards elimination (exit p=0.2) used to identify a final model. Where 
two variables were strongly co-linear, the variable with the strongest univariate association with 
cfPWV was considered for inclusion in the multivariate model. Independent effects of 
immunophenotyping parameters on this model were then also assessed. Overall changes in log10 
cfPWV over the first 44 weeks from enrolment were estimated using random effects models, 
considering the impact of HIV on cfPWV both at baseline (intercept) and over time (interaction with 
time). Regression models for cfPWV 44 weeks after enrolment in HIV-infected participants adjusted 
for baseline cfPWV and factors identified as confounders or mediators at baseline, and additionally 
considered the impact of immune parameters. Adjusting for baseline means these models identify 
predictors of change from baseline. 
 
All analysis was undertaken using Stata v13.1 (Statacorp, USA).  
 
Results 
 
2107 adults with a new HIV diagnosis were screened, of whom 279 (13%) were recruited. 170 (61%) 
were co-recruited with REALITY and 109 (39%) were not (Figure 1). Most exclusions [1477 (70%)] 
were due to CD4 >100 cells/mm
3
 (complete list in Supplementary Table 1). 110 HIV-uninfected 
adults were also recruited. Although the HIV-infected and uninfected groups were of similar age 
(median 36.6 versus 34.8 years, Table 1), HIV-infected participants were more likely to be male and 
have a lower level of education. Three (3%) HIV-uninfected versus five (2%) HIV-infected adults had 
a diagnosis of hypertension at enrolment; a further 46 (42%) and 88 (32%) respectively were 
discovered to have hypertension during the study. HIV-infected participants had advanced immune 
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suppression (median CD4 count 41 cells/L, median HIV viral load 5.06 log10 copies/ml), although 
only 54 (19%) were WHO HIV disease stage 3 or 4.  
 
All but one HIV-infected participant initiated standard first-line therapy with 
tenofovir+lamivudine+efavirenz (one zidovudine+lamivudine+nevirapine). In total, 28 (7%) 
participants withdrew or were lost to follow-up and 24 (6%) participants died. Of those lost to follow-
up or death, 13(29%) occurred within the first 2 weeks, 16(36%) between 2 and 10 weeks and 
16(36%) after 10 weeks (Figure 1). One HIV-uninfected participant died from a hypertension-related 
intra-cranial bleed. The 23 deaths in HIV-infected participants were due to pulmonary/disseminated 
TB (6), cryptococcal meningitis (3), Kaposi’s Sarcoma (3), gastroenteritis (1), and TB meningitis (1). 
The cause of death was unknown for 9 participants.  
 
Arterial stiffness at enrolment 
At enrolment, the median(IQR) cfPWV was 7.3 (IQR 6.5-8.2) m/s in HIV-infected versus 7.2 (6.2-
8.0) m/s in uninfected participants (p=0.07). cfPWV was greater than 12 m/s for 5 patients, 4 of whom 
had HIV infection. 
 
Immune activation at enrolment 
As expected, compared with HIV-uninfected participants, HIV-infected adults had higher activated 
(CD38+HLADR+) CD4 and CD8 T-cells (both p<0.0001). HIV-infected adults also had a higher 
proportion of exhausted (PD1+) CD4 and CD8 T-cells (both p<0.0001). In contrast, there were no 
differences between HIV-infected and uninfected participants in classical (CD14
++
CD16
-
), 
intermediate (CD14
++
CD16
+
) and non-classical (CD14
+
CD16
+
) monocytes (p=0.79, 0.10, 0.59 
respectively; Table 1).  
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T-cell PD1 expression is independently associated with HIV-related arterial stiffness 2 weeks post 
ART initiation 
Factors univariately associated with baseline cfPWV with p<0.2 are shown in Table 2A; neither WHO 
stage nor a diagnosis of acute co-infection were associated with baseline cfPWV (p=0.25 and 0.23 
respectively). Independently, every 10-year increase in age was associated with a 18% (95% CI 14-
23%) higher cfPWV (p<0.0001) (univariable associations in Supplementary Figure 3), with no 
evidence of effect modification between age and HIV (interaction p=0.73). Every 10mmHg higher 
diastolic blood pressure was also associated with a 9% (4-13%) higher cfPWV (p<0.0001), and 
women had 9% (2-16%) lower cfPWV (p=0.001). 
 
Adjusting for these confounders (Table 2A), there was weak evidence that HIV-infected participants 
had a 7% higher cfPWV (95% CI -1% to +16%, p=0.08). Adjusting for confounders and mediators, 
HIV was significantly associated with cfPWV, with a 12% higher cfPWV in HIV-infected 
participants (95% CI 2-23% p=0.02) (Table 2A). The effect of gender weakened with the addition of 
potential mediators (haemoglobin, weight, cholesterol, recent infection) to the model, but effects of 
age and diastolic blood pressure remained. cfPWV was 2% higher with every 1 g/dL higher 
haemoglobin (p=0.07), which may be a marker of plasma viscosity. Concurrent infection at HIV 
diagnosis was not associated with cfPWV [adjusted fold change +9% (95% CI -2% to +21%, p=0.13]. 
When immune variables were considered in addition to this model (Table 2B), exhausted CD4 and 
CD8 T-cells were each independently associated with cfPWV (p=0.02), and the independent effect of 
HIV was lost. HIV remained significantly associated with cfPWV excluding those with WHO stage 3 
and 4 (fold change 12% (95% CI 3 to 24%, p=0.01). 
 
HIV-related arterial stiffness improves on ART 
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At week-44, 228 (82%) HIV-infected and 103 (94%) uninfected participants remained on-study. All 
HIV-uninfected participants were retested for HIV at the week 44 visit and none had acquired a new 
infection.  
 
HIV-infected participants still had significantly higher cfPWV at week 10 (adjusted p=0.02), but not 
at week 22 or 44 (p=0.46 and 0.59, Figure 2). Overall, from enrolment through 44 weeks, cfPWV 
declined by 9% (95% CI 4 to 15%, p=0.002) in HIV-infected participants but did not change 
significantly in HIV-uninfected participants [change +2% (95% CI -7% to +12%, p=0.69; 
heterogeneity p=0.04].  In a sensitivity analysis, a similar effect of HIV on cfPWV was found at each 
timepoint when only including participants who completed the study: enrolment fold change +10% 
(CI interval 0% to 21%) , week 10 fold change +13% (CI interval +2% to +27%, p= 0.022), week 24 
fold change -4% (CI interval -13% to +6%, p=0.45) , week 44 fold change 3% (CI interval -7% to 
14%, p=0.60).  
 
For HIV-infected participants, median (IQR) CD4 count had increased to 144 (99-218) cells/uL. 
%CD8 T-cells decreased significantly (82% (84–96) to 60% (54–67), p<0.0001). Only %activated 
CD4 T-cells and %exhausted CD4 and CD8 T-cells decreased significantly by week-44 (74% (62–86) 
to 61% (50–69) p<0.0001; 54% (31-67) to 32% (22–48) p<0.0001; 38% (29–50) to 32% (21–47%) 
p=0.007 respectively, Supplementary Table 2). 
 
Resolution of higher CD8 T-cell PD1 expression is associated with lower arterial stiffness at 44 weeks 
post ART initiation  
Next, we examined the impact of baseline factors on cfPWV 44 weeks post ART initiation, adjusting 
for baseline cfPWV (equivalent to predictors for change in cfPWV) and age, sex, baseline 
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haemoglobin and diastolic blood pressure (Table 3). There was a trend towards higher %CD8PD1+ T-
cells at baseline being independently associated with lower arterial stiffness 44 weeks post ART 
initiation (4% lower week-44 cfPWV for every 10% higher %CD8PD1+ at enrolment, p=0.054). 
When REALITY intervention arms were added one by one to the same model (adjusted for age, sex, 
and baseline haemoglobin, diastolic blood pressure, CD8PD1+ T cells and baseline cfPWV), there 
was no evidence of association between week 44 cfPWV and randomisation to enhanced infection 
prophylaxis [fold change vs standard-prophylaxis 2% (95% CI -9% to +11%, p=0.76)]; or enhanced 
nutritional support [fold change vs standard support +8% (95% CI -3% to +20%, p=0.15)]. However, 
there was a trend towards lower adjusted cfPWV at week 44 in the 82 (29%) randomised to adjunctive 
raltegravir for 12 weeks at ART initiation [fold change vs standard ART alone -11% (95% CI -21 to -
1%, p=0.04)]. This effect of raltegravir on week 44 cfPWV was not lost by adding HIV viral load at 
baseline[-12% (95% CI -22 to 0%, p=0.05)], week 12 [-14% (95% CI -25% to 0%, p=0.04] or week 
24 [-12% (95% CI -24% to +1%, p=0.08]. 
 
Examining the relationship between change in immune markers and change in cfPWV from baseline 
to week 44, we found greater decreases in %CD8 T-cells, %CD8PD1+ T-cells and proportion of 
intermediate monocytes were associated with greater improvements in arterial stiffness univariably 
(p=0.01, p=0.03, p=0.054 respectively, Table 4). Adjusting for baseline factors as well as change in 
%CD8 and %CD8PD1+ T-cells, we found that the baseline effect of %CD8PD1+ cells on week 44 
cfPWV was attenuated and that there was instead a trend towards a lower cfPWV at week 44 in those 
with a greater decrease in %CD8PD1+ cells (p=0.079; Table 3). Overall, these data suggest that 
resolution of an initially high proportion of CD8 PD1+ T-cells is associated with an improvement in 
arterial stiffness over 44 weeks of ART.   
 
Discussion 
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We have demonstrated that arterial stiffness is increased in Malawian adults with advanced HIV 
during the first 3 months of ART and that T-cells expressing PD1 are associated with this effect. 
Further, we have shown that this effect is reversible, in a cohort initiating ART with severe 
immunosuppression and with only modest CD4 count gains on ART. Those with the highest 
proportion of PD1 expressing CD8 T-cells seemed to benefit the most from ART, demonstrating 
lower arterial stiffness 44 weeks post ART initiation. This is superimposed on a high background 
prevalence of hypertension.  
Hypertension was the most important traditional risk factor for cardiovascular disease.[29] Our 
findings are consistent with studies from the region showing 30-50% prevalence in the general 
population, with as few as 7% aware of their diagnosis.[30] In regions further along the 
epidemiological transition,[11] lifestyle-related CVD risk factors such as obesity and diabetes are 
becoming more important and are compounded by HIV infection.[31] Intervention to prevent CVD in 
low-income countries is urgently needed, before traditional risk factors intersect with the increased 
risk associated with HIV. 
 
HIV-infected participants had a 12% higher adjusted arterial stiffness at ART initiation compared to 
our HIV-uninfected population. Persisting higher arterial stiffness in the first 3 months of ART is 
consistent with work from Benjamin et al showing vasculitis as the pathological phenotype of 
vascular injury during this period, potentially reflecting an IRIS phenomenon.[32] Excess mortality 
during the first 3 months of ART is well-recognised in patients initiating ART with very low CD4 
counts.[10, 33] The REALITY trial assessed interventions to reduce this, but even with enhanced 
infection prophylaxis, 24-week mortality was still 8.9%.[34] Vascular inflammation, driven by high 
immune activation, may contribute to some of the adverse events seen during the first three months in 
those initiating ART with low CD4 counts. 
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In particular, CD8PD1+ T-cells have previously been associated with endothelial dysfunction in 
patients with HIV infection.[35-38] In a cross-sectional study of 358 participants of the SCOPE 
cohort (of whom 75% were virologically suppressed on ART), PD1+ T-cells were raised in untreated 
and treated HIV infection and CD8PD1+ expression was particularly associated with markers of HIV 
antigenaemia including CD8 T-cell activation and HIV viral load.[39] Given the association with 
reductions in arterial stiffness demonstrated here, the CD8PD1+ expression pathway warrants further 
investigation. However, in an environment where concurrent acute and latent infections are common, 
it may be that improvements in CD8PD1+ expression and arterial stiffness were not due to ART and 
control of HIV alone.[40, 41] Rather, there may have been a protective effect from cotrimoxazole co-
administration, preventing co-infections such as malaria or bacterial infections. An ‘ART care effect’ 
may have contributed to improvements over the study period, whereby patients who are engaged in 
care in a low-income setting experience benefits such as frequent monitoring or better access to care.  
 
Study strengths include prospective follow-up with robust assessment of clinical and cardiovascular 
measures, and a comprehensive longitudinal characterisation of both monocyte and T-cell surface 
activation markers from fresh PBMCs in a large cohort of HIV-infected and uninfected participants. 
As HIV is a generalised epidemic in Malawi, the HIV-infected population is likely to have a broadly 
similar traditional cardiovascular risk profile to HIV-uninfected adults enrolled from the same facility. 
Further, all but one of our participants received the same standard first-line ART regimen, meaning 
that choices relating to the specific ART regime cannot be confounders of the associations identified.  
 
Limitations include the fact that cfPWV has not been validated to predict cardiovascular events in 
low-income SSA, however, cfPWV has been validated robustly elsewhere.[42, 43] The relatively 
small differences identified in continuous cfPWV may have uncertain clinical relevance and our 
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hypothesised poor outcome (cfPWV>12 m/s) was rare; likely because our power calculations were 
based on studies from high-income settings, and much older populations than the HIV-infected 
population in SSA.[44-46] Overall, our study is still the largest to address this issue in the region, and 
demonstrates similar magnitudes of effect of HIV as traditional risk factors such as age (18% per 10 
years older) and blood pressure (9% per 10mmHg higher).  
 
Our HIV-uninfected population was selected to reflect generally healthy adults with similar socio-
demographics. Comparisons with our severely immunosuppressed HIV population therefore reflect 
the extremes, and this also limits the generalisability of our study to unselected HIV populations. 
However, WHO stage, CD4 count and the presence of co-infections and their clinical markers, were 
not independently associated with arterial stiffness, suggesting HIV effects may exist across the 
disease spectrum. Acute co-infections at the time of diagnosis were rare, limiting our power to assess 
their effects, but may have contributed to an IRIS type phenomenon. To avoid overburdening 
potentially clinically unwell patients who urgently needed to start ART, enrolment assessments were 
performed 2 weeks after ART initiation. As early mortality is high and some limited normalisation 
may have occurred, our findings are likely a best-case scenario.[24]  
 
Lastly, the size of the effect of CD8PD1+ T-cells on arterial stiffness was modest and is likely to 
represent one component of several concurrent complex mechanisms involved in the pathogenesis of 
endothelial damage in people with HIV in this setting. Nevertheless, exhaustion was the strongest 
immune predictor of cfPWV on ART, and other immunophenotyping parameters did not have 
independent effects after adjusting for PD1 expression.   
 
This is the first time that the dynamics of arterial stiffness in the first few months of ART have been 
documented longitudinally and related to cellular markers of immune activation in HIV-infected 
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adults. We have confirmed hypertension as the primary CVD risk factor in the region and 
demonstrated that consequences of immune activation can be reversed irrespective of CD4 recovery 
with early benefits for vasculature. Further studies into infection-driven immune activation, as a risk 
factor for CVD are warranted, but guidelines for prevention of CVD in HIV are urgently needed and 
should focus on hypertension reduction and close monitoring for those starting ART at lower CD4 
counts.  
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Table 1. Baseline characteristics according to HIV status 
  Complete 
cases  
HIV-uninfected n=110 
Median (IQR) or n (%) 
HIV-infected n=279 
Median (IQR) or n (%) 
p value 
Demographics       
 Age 388 34.8 (30.8 – 41.2) 36.6 (31.1 – 43.3) 0.41 
 Female 389 66 (60%) 122 (44%) 0.004 
 Primary school education or 
less 
352 38 (40%) 136 (53%) 0.024 
Traditional CV risk 
factors 
     
 Weight (kg) 375 60 (53 - 68) 53 (48 - 59) <0.0001 
 Waist: height ratiob 349 0.47 (0.44 – 0.53) 0.45 (0.43 – 0.49) 0.0003 
 BMI (kg/m2) 373 21.7 (20.2 – 25.2) 19.8 (18.3 – 21.9) <0.0001 
 Systolic BP (mmHg) 361 128 (114 - 134) 120 (108 - 128) 0.0001 
 Diastolic BP (mmHg) 358 75 (68 - 82) 73 (68 - 80) 0.27 
 History of smokingc 389 16 (15%) 56 (20%) 0.21 
 History of alcohol usec 389 28 (25%) 119 (43%) 0.002 
 Pre-existing CV diagnosis 370 1 (1%) 1 (0.4%) 0.47 
 Prescribed CV medications 370 5 (5%) 4 (1.5%) 0.08 
 Pre-existing diabetes 367 1 (1.0%) 1 (0.4%) 0.65 
 Pre-existing hypertension 366 3 (3.0%) 5 (2.0%) 0.40 
 New diagnosis of hypertension 358 46 (42%) 88 (32%) 0.055 
 Fasting cholesterol (mmol/L) 377 4.0 (3.3 – 4.5) 3.6 (3.0 – 4.4) 0.049 
 Fasting glucose (mmol/L) 327 4.6 (4.2 – 5.2) 4.9 (4.4 – 5.6) 0.015 
 Creatinine (µmol/L) 381 62 (54 - 71) 65 (54 - 78) 0.13 
Infection related 
factors 
     
 Heart rate (bpm) 360 72 (68 - 80) 82 (72 - 98) <0.0001 
 Haemoglobin (g/dL) 375 13.8 (12.7 – 14.7) 11.4 (10.0 – 13.0) <0.0001 
 Current infection at enrolment 377 3 (3%)a 57 (21%) <0.0001 
 TB  0 (0%) 2 (1%) - 
 Cryptococcal meningitis  0 (0%) 0 (0%) - 
 Pneumonia  0 (0%) 10 (4%) - 
 Gastroenteritis  1 (1%) 17 (6%) - 
 Malaria  2 (2%) 3 (1%) - 
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/advance-article-abstract/doi/10.1093/infdis/jiz015/5283190 by U
niversity of Liverpool user on 18 January 2019
Ac
ce
pte
d M
an
us
cri
pt
28 
 
 
  Complete 
cases  
HIV-uninfected n=110 
Median (IQR) or n (%) 
HIV-infected n=279 
Median (IQR) or n (%) 
p value 
Immune related 
factors 
     
 Lymphocytes (x109/L) 370 2.1 (1.6 – 2.6) 1.2 (0.8 – 1.7) <0.0001 
 Monocytes (x109/L) 323 0.30 (0.25 – 0.50) 0.40 (0.22 – 0.60) 0.053 
 Absolute CD4 count (cells/µL)  - 41 (18 - 62) - 
 HIV viral load  
(log10 copies/mL) 
 - 5.06 (4.62 – 5.47) - 
 %CD4 Activated 
(CD38+HLADR+) 
193 5% (3–9) 22% (11–34) <0.0001 
 %CD8 Activated 
(CD38+HLADR+)  
290 11% (6–19) 34% (21–49) <0.0001 
 %CD4 Senescent  
(PD1+) 
194 7% (4–9) 15% (9–24) 0.0001 
 %CD8 Senescent 
(PD1+)  
295 40% (27–53) 54% (44–64) <0.0001 
 Classical Monocytes 
(CD14++CD16-) 
263 75% (65–81) 76% (66–83) 0.79 
 Intermediate Monocytes 
(CD14++CD16+) 
263 9% (7–14) 10% (6–13) 0.10 
 Non-classical Monocytes 
(CD14+CD16+) 
263 13% (10–22) 14% (9–21) 0.59 
aBased on tests returned after enrolment at which point the participants reported, and physician confirmed, absence of infection. 
bWaist:height ratio measures central obesity, a risk factor for metabolic syndrome. [47]   
cDefined as either a past or current history of regular alcohol or smoking.
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Table 2A. Predictors of carotid femoral Pulse Wave Velocity adult Malawians at enrolment 
  Univariate analysis 
 
Multivariate analysis including confounders  
N= 353 complete cases 
Multivariate analysis including 
mediators and confounders  
n=335 complete cases 
 N 
evaluable 
Fold change 
in cfPWVb 
P value 95% CI  
  
Fold change 
in cfPWVb 
P value 95% CI Fold 
change in 
cfPWVb  
P value 95% CI  
  
 HIV 366 1.09 0.06 0.44 2.68 1.07 0.08 0.99 1.16 1.12 0.02 1.02 1.23 
Potential 
confoundersa 
              
 Age (per 10-year older) 366 1.23 <0.0001 1.18 1.27 1.18 <0.0001 1.14 1.23 1.18 <0.0001 1.13 1.23 
 Female (vs male) 366 0.87 0.001 0.80 0.94 0.91 0.01 0.84 0.98 0.94 0.15 0.86 1.02 
 Diastolic BP (per 10 mmHg 
higher) 
353 1.13 <0.0001 1.09 1.18 1.09 <0.0001 1.04 1.13 1.07 0.001 1.03 1.13 
Potential mediatorsa               
 Haemoglobin (per g/dL higher) 355 1.02 0.07 1.00 1.03 - - - - 1.02 0.07 1.00 1.04 
 Weight (per 10kg higher) 363 1.05 0.02 1.01 1.09 - - - - 1.01 0.58 0.97 1.05 
 Cholesterol (per mmol/L higher) 357 1.04 0.09 1.00 1.08 - - - - 0.99 0.62 0.95 1.03 
 Recent acute infection 364 1.11 0.08 0.99 1.25 - - - - 1.09 0.11 0.98 1.22 
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Table 2B. Effect of the addition of T-cell exhaustion markers on the relationship between HIV and cfPWV 
 Traditional risk factors model with HIV status 
added 
n=335 
Traditional risk factors model with CD4 
Exhaustion 
n=181 
Traditional risk factors model with CD8 
Exhaustion 
n=270 
Fold change in 
cfPWVb  
P value 95% CI   Fold change in cfPWVb  P value 95% CI    Fold change in cfPWVb  P value 95% CI   
Age (per 10-year older) 1.18 <0.0001 1.13 1.23 1.15 <0.0001 1.10 1.21 1.15 <0.0001 1.10 1.20 
Female (vs male) 0.92 0.02 0.85 0.99 0.83 <0.0001 0.74 0.92 0.88 0.006 0.81 0.96 
Diastolic BP (per 10mmHg higher) 1.07 0.001 1.03 1.13 1.10 0.01 1.04 1.17 1.10 <0.0001 1.05 1.15 
Haemoglobin (per g/dL higher) 1.02 0.07 1.00 1.04 1.01 0.36 0.99 1.04 1.01 0.21 0.99 1.03 
HIV infection 1.12 0.02 1.02 1.23 1.00 0.96 0.86 1.15 1.05 0.40 0.94 1.17 
CD4 T-cell exhaustion (per 10% higher) - - - - 1.03 0.02 1.00 1.05 - - - - 
CD8 T-cell exhaustion (per 10% higher) - - - - - - - - 1.03 0.02 1.00 1.05 
a
 see Supplementary Material Figure 2 for Directed Acyclic Graph and identification of confounders vs mediators. b log10 cfPWV was the outcome in linear regression 
models, providing model coefficients that correspond to fold (relative) changes when back transformed. Table 2A includes all relevant variables with p<0.2 for 
association with cfPWV in univariable analyses. Table 2B uses backwards elimination to select a final model from confounders and mediators in Table 2A and then 
considers additional effects of CD4 or CD8 exhaustion (similar effects in a model including both, n=178). There was no association between CD4/CD8 T-cell activation 
or CD4/CD8 senescence on cfPWV (p=0.77, 0.37, 0.98, 0.15 respectively) 
D
ow
nloaded from
 https://academ
ic.oup.com
/jid/advance-article-abstract/doi/10.1093/infdis/jiz015/5283190 by U
niversity of Liverpool user on 18 January 2019
Ac
ce
pte
d M
an
us
cri
pt
31 
 
 
Table 3. Factors associated with arterial stiffness at 44 weeks post ART initiation in HIV-infected adults 
 Baseline factors only n=237 Baseline factors and change from baseline to week 44* n=174 
 Fold change  P value 95% Confidence Intervals  Fold change  P value 95% Confidence Intervals  
Baseline cfPWV (m/s) (per m/s higher) 2.70 <0.0001 1.83 4.00 1.15 <0.0001 1.09 1.22 
Age (per 10 years older) 1.20 <0.0001 1.11 1.30 1.21 <0.0001 1.11 1.32 
Baseline haemoglobin (per g/dL higher) 1.03 0.037 1.00 1.06 1.04 0.027 1.00 1.07 
Baseline %CD8PD1+ (per 10% higher) 0.96 0.054 0.91 1.00 0.99 0.71 0.95 1.03 
Change in %CD8PD1+ (per 10% higher) over 44 weeks - - - - 1.02 0.079 1.00 1.05 
Change in %CD8 (per 10% higher) over 44 weeks - - - - 1.04 0.13 0.99 1.09 
* including factors with univariable p<0.05 from Table 4 
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Table 4. Change in clinical and immune parameters and association with change in arterial 
stiffness 44 weeks post enrolment in HIV-infected adults  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Rho P value 
Δ Systolic BP (mmHg) 0.03 0.72 
Δ Diastolic BP (mmHg) 0.07 0.29 
Δ Weight (Kg) -0.09 0.21 
Δ Creatinine (µmol/L) 0.01 0.88 
Δ Haemoglobin (g/dL) 0.03 0.72 
Δ HIV viral load (copies/µL) -0.08 0.28 
Δ CD4 count (cells/µL) -0.04 0.64 
Δ %CD8 0.21 0.01 
Δ CD4/CD8 ratio -0.13 0.12 
Δ %CD4 Activation 0.03 0.79 
Δ %CD4 Exhaustion 0.14 0.22 
Δ %CD4 Senescence 0.13 0.24 
Δ %CD8 Activation -0.03 0.72 
Δ %CD8 Exhaustion  0.19 0.03 
Δ %CD8 Senescence 0.04 0.67 
Δ %Classical Monocytes -0.16 0.07 
Δ %Intermediate Monocytes 0.18 0.054 
Δ %Non-classical Monocytes 0.01 0.91 
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Figure 1. Recruitment Flow 
Enrolment was carried out 2 weeks after screening 
Figure 2. Adjusted effect of HIV on cfPWV over 44 weeks 
Legend: The graph shows the effect of HIV on fold change in cfPWV adjusted for age, sex, diastolic 
blood pressure and haemoglobin. The same model is calculated for each individual timepoint. 
a
The 
table below the graph shows the mean cfPWV and 95% confidence intervals according to HIV status 
at each timepoint. 
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